ClinicalTrials.gg
CompletedNCT01156259Updated Oct 28, 2026

30Gy Versus 40Gy Radiotherapy for Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy

A Phase 3 interventional study of Consolidative radiotherapy at 30 Gy and Consolidative radiotherapy at 40 Gy in Lymphoma, Large B-cell, Diffuse, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Completed at 1 site in China. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Phase 3, Interventional, and Treatment

How we know

Updated Oct 28, 2026Now CompletedPrimary completion moved+10 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
432
Allocation
Randomized
Ages
15 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 306 studies in Lymphoma, Large B-Cell, Diffuse with a site in China — 143 open to participants now, 165 under way, 31 of them phase 3. Lymphoma, Large B-Cell, Diffuse · China.

Enrollment
22nd of 277
432 · median 59
Started
2010
with 2 others
Phase 3
57 of 306
18 open now
Registered
5th of 306
by date

Among the 306 studies in Lymphoma, Large B-Cell, Diffuse with a site in China, this one is the 22nd largest by enrollment of the 277 interventional ones that give a count, is one of 3 that started in 2010, is one of 57 in phase 3, and was the 5th registered.

Lymphoma, Large B-Cell, Diffuse

1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

143 of the 306 studies in Lymphoma, Large B-Cell, Diffuse with a site in China are open now. Recruiting first, the newest first:

138 more — sign in →

All 143 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 265 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 176 (66%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 15 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 306 studies in Lymphoma, Large B-Cell, Diffuse with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether 30Gy radiotherapy is as effective as 40Gy in the treatment of localized Diffused Large B cell Lymphoma (DLBCL) when completing CR after chemotherapy.

Read the detailed description

The best proper doses of RT in combined modality treatments (CMT) for localized DLBCL is still undetermined. Existing treatment guidelines recommend 40Gy or above as the standard treatment dosage. However, there were large-scaled clinical trials implying smaller doses such as 30Gy may be equivalent effective. Lowering radiation doses can decrease treatment toxicities and radiotherapy-induced diseases, which has been conformed by HD13 study for Hodgkin's Lymphoma. It may even retain the truth when modern era radiation techniques are involved and especially in patients achieving CR after chemotherapy. A comprehensive, prospective dose-comparing study is needed.

03

Conditions studied

  • Lymphoma, Large B-cell, Diffuse

Keywords

  • B cell cll/lymphoma, human
04

Who can participate

The criteria were revised on the registry on Oct 23, 2026. See what changed

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written obtained before any trial-specific procedure.
  2. Age 15 years or older.
  3. Newly diagnosed, confirmed DLBCL or primary mediastinal B-cell lymphoma (PMBL).
  4. Ann Arbor stage I or II disease.
  5. Complete response after chemotherapy, defined as the absence of clinical or imaging evidence of active disease, or a Deauville score of 1-3 on PET/CT.
  6. An interval of less than 90 days between completion of chemotherapy and radiotherapy.
  7. (ECOG) performance status of 0-2.
  8. Able to receive conformal radiotherapy and to complete the required follow-up.

Exclusion criteria

Exclusion Criteria:

  1. seropositivity.
  2. Primary lymphoma of the central nervous system, skin, or testis.
  3. Transformation from another indolent lymphoma.
  4. Previous other than cervical carcinoma in situ.
  5. Hepatic or cardiac failure.
  6. Any concurrent condition precluding protocol treatment.
  7. Chemotherapy or radiotherapy before trial enrolment.
  8. Pregnancy or breastfeeding.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
432 participants (actual)

Study arms

  • Experimental
    30 Gy

    Radiation: Consolidative radiotherapy at 30 Gy

  • Active comparator
    40 Gy

    Radiation: Consolidative radiotherapy at 40 Gy

Interventions

  • RadiationConsolidative radiotherapy at 30 Gy

    CT simulation, 3D-CRT or IMRT techniques, Radiotherapy of 30Gy

  • RadiationConsolidative radiotherapy at 40 Gy

    CT simulation, 3D-CRT or IMRT techniques, Radiotherapy of 40Gy

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS)

    the time from randomisation to disease progression, relapse, or death from any cause, whichever occurred first

    Time frame: five years

Secondary outcomes

  1. overall survival

    Time frame: five years

  2. acute treatment toxicity

    Time frame: 90 days

  3. late treatment toxicity

    Time frame: five years

  4. treatment failure type

    freedom from locoregional recurrence (FFLR), distant metastasis-free survival (DMFS)

    Time frame: five years

07

Study locations

1 site
  • Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
    Beijing, Beijing Municipality 100021, China
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2010 to primary completion in Jul 2025, 180 months.

Of 73 phase 3 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 99. This study's 180 months is above that.

Start moved once since we started tracking on Sep 25, 2026: Apr 2010 → Jul 2010, on Oct 23, 2026.

Primary completion moved twice since we started tracking on Sep 25, 2026: Apr 2015 → Jul 2025, last on Oct 28, 2026.

Completion moved once since we started tracking on Sep 25, 2026: May 2015 → Jul 2025, on Oct 23, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2010
First posted
Jul 2, 2010
StartActual
Jul 14, 2010was Apr 2010
Primary completionActual
Jul 2025was Apr 2015
CompletionActual
Jul 2025was May 2015
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Oct 23, 2026
Sites
1 site added, 1 site removed
Show site
  • Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College · Beijing, China
Show 1 removed
  • Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College · Beijing, China
Oct 23, 2026
Start date
Apr 2010→Jul 14, 2010 (actual)
Oct 23, 2026
Primary completion
Apr 2015→Jul 2025
moved 2 times, Oct 23, 2026 – Oct 28, 2026
Study completion
May 2015→Jul 2025 (actual)
Oct 23, 2026
Enrollment
400 (estimated)→432 (actual)
Oct 23, 2026
Eligibility
Criteria largely rewritten (31 changes)
What changed in the criteria
Inclusion criteria
  • Removedbiopsy-proved Diffuse Large B cell lymphoma
  • Removednonbulky stage I, nonbulky stage IE, nonbulky stage II, or nonbulky stage IIE disease(Bulky disease was defined as a mass 10 cm or more in maximal diameter) according to Ann Arbor Staging
  • Removedprovide written informed consent
  • RemovedComplete regression after chemotherapy
  • RemovedConsiderable to CT simulation and 3D CRT or IMRT
  • RemovedPerformance status 0-2 WHO criteria;life expectation>6 months
  • Removednegative for human immunodeficiency virus syndrome (HIV)
  • RemovedMinimal staging included chest radiograph, computed tomography of the abdomen and pelvis, and single percutaneous bone marrow biopsy and blood studies
  • AddedWritten informed consent obtained before any trial-specific procedure.
  • AddedAge 15 years or older.
  • AddedNewly diagnosed, histologically confirmed DLBCL or primary mediastinal B-cell lymphoma (PMBL).
  • AddedAnn Arbor stage I or II disease.
  • AddedComplete response after chemotherapy, defined as the absence of clinical or imaging evidence of active disease, or a Deauville score of 1-3 on PET/CT.
  • AddedAn interval of less than 90 days between completion of chemotherapy and radiotherapy.
  • AddedEastern Cooperative Oncology Group (ECOG) performance status of 0-2.
  • AddedAble to receive conformal radiotherapy and to complete the required follow-up.
Exclusion criteria
  • Removedprimary mediastinal large B cell lymphoma
  • Removeddermatological lymphoma
  • Removedtesticular lymphoma
  • Removedprimary central nerve system lymphoma
  • Removedprior RT
  • Removedhistory of low-grade lymphoma congestive
  • Removedhistory of heart failure (CHF; New York Heart Association [NYHA] classifications III-IV), history of neoplasm (adequately treated basal cell carcinoma of the skin or in situ carcinoma of the uterine cervix were allowed), abnormal liver function tests (aminotransferases and alkaline phosphatase > 2.5 times the upper limit of normal, bilirubin > 50 ), renal insufficiency (serum creatinine > 300 ), and patients with any serious medical or psychiatric illness that would prevent informed consent or completion of protocol-prescribed treatment and follow-up
  • AddedHIV seropositivity.
  • AddedPrimary lymphoma of the central nervous system, skin, or testis.
  • AddedTransformation from another indolent lymphoma.
  • AddedPrevious malignancy other than cervical carcinoma in situ.
  • AddedHepatic or cardiac failure.
  • AddedAny concurrent condition precluding protocol treatment.
  • AddedChemotherapy or radiotherapy before trial enrolment.
  • AddedPregnancy or breastfeeding.
Oct 23, 2026
Interventions
Added Radiation: Consolidative radiotherapy at 30 Gy·Radiation: Consolidative radiotherapy at 40 Gy; removed Radiation: 3D-CRT based Involved Field Radiotherapy
across 2 updates, Oct 23, 2026 – Oct 28, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore disease free survivalNow Progression-free survival (PFS)Time frame: five years
Oct 23, 2026
Secondary outcomes
Revised in 2 updates
What changed on Oct 23, 2026
  • Time frameacute treatment toxicityup to 16 weeks → up to 12 weeks
  • Descriptiontreatment failure type: how it is measured was reworded
What changed on Oct 28, 2026
  • Time frameacute treatment toxicityup to 12 weeks → 90 days
across 2 updates, Oct 23, 2026 – Oct 28, 2026
Title
30Gy Versus 40Gy Involved-field Radiotherapy for Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy
Oct 23, 2026
Sponsor
Chinese Academy of Medical Sciences→Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Collaborators added: Sun Yat-Sen University Cancer Center; collaborators removed: Sun Yat-sen University
Oct 23, 2026
Show all 2 updates
  1. Oct 28, 2026
    Primary completion Jul 1, 2019→Jul 2025
    Secondary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameacute treatment toxicityup to 12 weeks → 90 days
    Interventions Added Radiation: Consolidative radiotherapy at 30 Gy·Radiation: Consolidative radiotherapy at 40 Gy; removed Radiation: Radiotherapy followed by chemotherapy·Radiation: 3D-CRT based Involved Field Radiotherapy
    + 2 other changes: identifiers and oversight details
  2. Oct 23, 2026
    Status unknown→Completed
    1 site added, 1 site removed
    Show site
    • Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College · Beijing, China
    Show 1 removed
    • Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College · Beijing, China
    Start date Apr 2010→Jul 14, 2010 (now actual)
    Primary completion Apr 2015→Jul 1, 2019 (now actual)
    Study completion May 2015→Jul 2025 (now actual)
    Enrollment 400 (estimated)→432 (actual)
    Eligibility Criteria largely rewritten (31 changes)
    What changed in the criteria
    Inclusion criteria
    • Removedbiopsy-proved Diffuse Large B cell lymphoma
    • Removednonbulky stage I, nonbulky stage IE, nonbulky stage II, or nonbulky stage IIE disease(Bulky disease was defined as a mass 10 cm or more in maximal diameter) according to Ann Arbor Staging
    • Removedprovide written informed consent
    • RemovedComplete regression after chemotherapy
    • RemovedConsiderable to CT simulation and 3D CRT or IMRT
    • RemovedPerformance status 0-2 WHO criteria;life expectation>6 months
    • Removednegative for human immunodeficiency virus syndrome (HIV)
    • RemovedMinimal staging included chest radiograph, computed tomography of the abdomen and pelvis, and single percutaneous bone marrow biopsy and blood studies
    • AddedWritten informed consent obtained before any trial-specific procedure.
    • AddedAge 15 years or older.
    • AddedNewly diagnosed, histologically confirmed DLBCL or primary mediastinal B-cell lymphoma (PMBL).
    • AddedAnn Arbor stage I or II disease.
    • AddedComplete response after chemotherapy, defined as the absence of clinical or imaging evidence of active disease, or a Deauville score of 1-3 on PET/CT.
    • AddedAn interval of less than 90 days between completion of chemotherapy and radiotherapy.
    • AddedEastern Cooperative Oncology Group (ECOG) performance status of 0-2.
    • AddedAble to receive conformal radiotherapy and to complete the required follow-up.
    Exclusion criteria
    • Removedprimary mediastinal large B cell lymphoma
    • Removeddermatological lymphoma
    • Removedtesticular lymphoma
    • Removedprimary central nerve system lymphoma
    • Removedprior RT
    • Removedhistory of low-grade lymphoma congestive
    • Removedhistory of heart failure (CHF; New York Heart Association [NYHA] classifications III-IV), history of neoplasm (adequately treated basal cell carcinoma of the skin or in situ carcinoma of the uterine cervix were allowed), abnormal liver function tests (aminotransferases and alkaline phosphatase > 2.5 times the upper limit of normal, bilirubin > 50 ), renal insufficiency (serum creatinine > 300 ), and patients with any serious medical or psychiatric illness that would prevent informed consent or completion of protocol-prescribed treatment and follow-up
    • AddedHIV seropositivity.
    • AddedPrimary lymphoma of the central nervous system, skin, or testis.
    • AddedTransformation from another indolent lymphoma.
    • AddedPrevious malignancy other than cervical carcinoma in situ.
    • AddedHepatic or cardiac failure.
    • AddedAny concurrent condition precluding protocol treatment.
    • AddedChemotherapy or radiotherapy before trial enrolment.
    • AddedPregnancy or breastfeeding.
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore disease free survivalNow Progression-free survival (PFS)Time frame: five years
    Secondary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameacute treatment toxicityup to 16 weeks → up to 12 weeks
    • Descriptiontreatment failure type: how it is measured was reworded
    Interventions Added Radiation: Radiotherapy followed by chemotherapy; removed Radiation: 3D-CRT based Involved Field Radiotherapy
    Sponsor Chinese Academy of Medical Sciences→Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Collaborators added: Sun Yat-Sen University Cancer Center; collaborators removed: Sun Yat-sen University
    Title 30Gy Versus 40Gy Involved-field Radiotherapy for Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy
    + 5 other changes: description, conditions, design details, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT01156259
Collaborators
Sun Yat-Sen University Cancer Center
Responsible party
Shunan Qi (Chief Physician, Cancer Institute and Hospital, Chinese Academy of Medical Sciences) — Principal investigator
First posted
Jul 2, 2010
Start date
Jul 14, 2010
Primary completion
Jul 2025
Completion
Jul 2025
Last update
Oct 28, 2026

Study contacts

Yexiong Li, MD
study director · Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion